Abstract

Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study
Matthew S Davids ... Ulrich Jaeger
Blood | VOL. 132
Matthew S Davids, et. al.Matthew S Davids ... Ulrich Jaeger
29 Nov 2018
Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study
Jennifer R Brown ... Florence Cymbalista
Blood | VOL. 132
Jennifer R Brown, et. al.Jennifer R Brown ... Florence Cymbalista
29 Nov 2018
Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study
Michael Wang ...
Blood | VOL. 138
Michael Wang, et. al.Michael Wang ...
05 Nov 2021
Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase
Steven M Horwitz ... Jasmine Zain
Blood | VOL. 134
Steven M Horwitz, et. al.Steven M Horwitz ... Jasmine Zain
13 Nov 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
CDK9 phosphorylates RUNX1 to promote megakaryocytic fate in megakaryocytic-erythroid progenitors.
Nayoung Kwon ... Diane S Krause
Blood | VOL. -
Nayoung Kwon, et. al.Nayoung Kwon ... Diane S Krause
05 Aug 2024
Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study.
David T Yeung ... Timothy P Hughes
Blood | VOL. -
David T Yeung, et. al.David T Yeung ... Timothy P Hughes
05 Aug 2024
Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.
Esteban Arrieta-Bolaños ... Katharina Fleischhauer
Blood | VOL. -
Esteban Arrieta-Bolaños, et. al.Esteban Arrieta-Bolaños ... Katharina Fleischhauer
05 Aug 2024
NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression
Belén Lopez-Millan ... Clara Bueno
Blood | VOL. -
Belén Lopez-Millan, et. al.Belén Lopez-Millan ... Clara Bueno
02 Aug 2024
View more papers